Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Draft guidance proposals from industry allowed under FDA "good guidance practices" policy.

This article was originally published in The Gray Sheet

Executive Summary

DRAFT GUIDANCE PROPOSALS BY INDUSTRY TO FDA PERMITTED under the agency's "good guidance practices" policy published in Feb. 27 Federal Register. The GGP includes a "guidance proposal policy" whereby the public will have "an opportunity to propose topics for new or revised guidance or to propose draft guidance documents." FDA says it is allowing members of the public to propose guidance to encourage input during the guidance development and revision process.

You may also be interested in...



FDA/Industry Poised To Form Task Force On Industry Role In Guidance Process

FDA's Center for Devices and Radiological Health and industry reps are considering the formation of a joint task force to look at ways of increasing industry participation in the drafting and development of the agency's guidance documents.

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT007615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel